Promoted Content

Promoted Content

X

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Addex Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

CPhI North America Online

Participation Not Confirmed

Update your events

Addex Receives Additional $2.8 Million from Indivior and Extends Gabab Pam Research Collaboration

Contact the Supplier

Lead Product(s): Undisclosed

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: Indivior

Deal Size: $330.0 million Upfront Cash: $5.0 million

Deal Type: Collaboration November 02, 2020

Details:

The collaboration covers the discovery of novel oral gamma-aminobutyric acid receptor subtype B (GABAB) positive allosteric modulator (PAM) compounds as potential therapies for multiple disease areas.